SEC Form SC 13G/A filed by Oncocyte Corporation (Amendment)

2/14/24 5:03:19 PM ET

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Get the next $OCX alert in real time by email

SC 13G/A 1 oxc13g.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 5)* Oncocyte Corp (Name of Issuer) Common Stock, No. Par Value (Title of Class of Securities) 68235C107 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ X ] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 68235C107 13G Page 2 of 9 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Pura Vida Investments, LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 708,172* 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 708,172* 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 708,172* 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.45%** 12. TYPE OF REPORTING PERSON (see instructions) IA CUSIP No. 68235C107 13G Page 3 of 9 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Efrem Kamen 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 708,172* 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 708,172* 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 708,172* 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.45%** 12. TYPE OF REPORTING PERSON (see instructions) IN, HC CUSIP No. 68235C107 13G Page 4 of 9 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Pura Vida Master Fund, Ltd. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 309,823*** 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 309,823*** 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 309,823*** 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.73%**** 12. TYPE OF REPORTING PERSON (see instructions) OO CUSIP No. 68235C107 13G Page 5 of 9 Pages Item 1. (a) Name of Issuer Oncocyte Corp (b) Address of Issuers Principal Executive Offices 15 Cushing, Irvine, CA, 92618 Item 2. (a) Name of Person Filing Pura Vida Investments, LLC Pura Vida Master Fund, Ltd. Efrem Kamen (collectively, the "Reporting Persons"). (b) The address of the principal place of the Reporting Persons is located at: Pura Vida Investments, LLC 545 West 25th Street, 19th Floor New York, NY, 10001 (c) For citizenship of the Reporting Persons, see Item 4 of the cover sheet for each Reporting Persons. (d) Title of Class of Securities Common Stock, No Par Value (e) CUSIP Number 68235C107 Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [x] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J). CUSIP No. 68235C107 13G Page 6 of 9 Pages Item 4. Ownership. (a) Amount beneficially owned: Pura Vida Investments LLC 708,172* shares Efrem Kamen 708,172* shares Pura Vida Master Fund, Ltd. 309,823*** shares (b) Percent of class: Pura Vida Investments LLC 8.45%** Efrem Kamen 8.45%** Pura Vida Master Fund, Ltd. 3.73%**** (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: Pura Vida Investments 708,172* shares Efrem Kamen 708,172* shares Pura Vida Master Fund, Ltd. 309,823*** shares (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: Pura Vida Investments, LLC 708,172* shares Efrem Kamen 708,172* shares Pura Vida Master Fund, Ltd. 309,823*** shares * Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund) and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. By virtue of these relationships, the PVI and Efrem Kamen may be deemed to have shared voting and dispositive power with respect to the shares owned directly by the Client Accounts. This report shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the shares for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the shares reported herein except to the extent of PVIs and Efrem Kamens pecuniary interest therein, if any. As of the date of this filing, shares reported herein for the Reporting Persons include (1) 586,930 shares of Common Stock of the Issuer outstanding and (2) warrants to acquire up to 121,242 shares of Common Stock of the Issuer. CUSIP No. 68235C107 13G Page 7 of 9 Pages **The percentages herein are calculated based upon (1) 8,260,762 shares of Common Stock of the Issuer outstanding per the Issuers Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023 and (2) 121,242 shares of Common Stock of the Issuer issuable upon exercise of warrants owned by the Reporting Persons, which have been added to the total shares of Common Stock of the Issuer outstanding pursuant to Rule 12d-3(d)(3) under the Act. *** Shares reported herein are owned by the Pura Vida Master Fund. PVI serves as the investment manager to the Pura Vida Master Fund. Efrem Kamen serves as the Managing Member of PVI. By virtue of these relationships, PVI and Efrem Kamen may be deemed to have shared voting and dispositive power with respect to the shares owned directly by the Pura Vida Master Fund. This report shall not be deemed an admission that PVI and Efrem Kamen are beneficial owners of the shares for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of PVI and Efrem Kamen disclaims beneficial ownership of the shares reported herein except to the extent of PVIs and Efrem Kamens pecuniary interest therein, if any. As of the date of this filing, shares reported herein for the Pura Vida Master Fund include (1) 268,176 shares of Common Stock of the Issuer outstanding and (2) warrants to acquire up to 41,647 shares of Common Stock of the Issuer. ****The percentages herein are calculated based upon (1) 8,260,762 shares of Common Stock of the Issuer outstanding per the Issuers Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023 and (2) 41,647 shares of Common Stock of the Issuer issuable upon exercise of warrants owned by the Pura Vida Master Fund, which have been added to the total shares of Common Stock of the Issuer outstanding pursuant to Rule 12d-3(d)(3) under the Act. Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, Pura Vida Master Fund, Ltd. has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X] Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. N/A Item 8. Identification and Classification of Members of the Group. N/A Item 9. Notice of Dissolution of Group. N/A Item 10. Certification. CUSIP No. 68235C107 13G Page 8 of 9 Pages By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Exhibits. Exhibit A Joint Filing Agreement. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 14, 2024 Pura Vida Investments, LLC By: /s/ Efrem Kamen, Managing Member CUSIP No. 68235C107 13G Page 9 of 9 Pages EXHIBIT A AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Pura Vida Investments, LLC. beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties hereto further consent this Statement pursuant to Rule 13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule 13G. Dated: February 14, 2024 Pura Vida Investments, LLC By: /s/ Efrem Kamen, Managing Member

Get the next $OCX alert in real time by email

Date	Price Target	Rating	Analyst
3/28/2025	$5.00	Buy	Lake Street
5/24/2022		Overweight → Equal-Weight	Stephens
3/14/2022		Overweight → Sector Weight	KeyBanc Capital Markets
3/11/2022	$11.00 → $6.00	Buy	Lake Street
3/11/2022	$5.00 → $4.00	Buy	Needham
1/7/2022	$3.10	Overweight	Stephens & Co.
1/6/2022	$3.10	Overweight	Piper Sandler
12/16/2021	$7.00 → $5.00	Buy	Needham

SEC Form SC 13G/A filed by Oncocyte Corporation (Amendment)

Chat with this insight

Recent Analyst Ratings for $OCX

$OCX Press Releases

Fastest customizable press release news feed in the world

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Oncocyte Provides Positive Update on Clinical Trial Progress

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

$OCX Financials

Live finance-specific insights

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Oncocyte Provides Positive Update on Clinical Trial Progress

STAAR Surgical Announces Changes to Board of Directors

$OCX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Lake Street initiated coverage on OncoCyte with a new price target

OncoCyte downgraded by Stephens

OncoCyte downgraded by KeyBanc Capital Markets

$OCX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

SEC Form SC 13G filed by Oncocyte Corporation

Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

$OCX Leadership Updates

Live Leadership Updates

$OCX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$OCX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Veradigm Announces Board Expansion and Changes

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

Chief Financial Officer James Andrea S. bought $200,000 worth of shares (97,561 units at $2.05), increasing direct ownership by 182% to 151,231 units (SEC Form 4)

Large owner Smith Patrick W bought $2,209,080 worth of shares (1,077,600 units at $2.05) and acquired $790,919 worth of shares (385,814 units at $2.05) (SEC Form 4)

Large owner Broadwood Partners, L.P. bought $10,589,675 worth of shares (5,165,695 units at $2.05) (SEC Form 4)

SEC Form 4 filed by Chief Financial Officer James Andrea S.

SEC Form 4 filed by VP ACCT, Cntlr, Treasurer, PAO Liu James Yang

SEC Form 4 filed by CEO and President Riggs Josh

$OCX SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Oncocyte Corporation

Oncocyte Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

SEC Form 424B3 filed by Oncocyte Corporation

Recent Analyst Ratings for
$OCX

$OCX
Press Releases

$OCX
Financials

$OCX
Analyst Ratings

$OCX
Large Ownership Changes

$OCX
Leadership Updates

$OCX
Insider Purchases

$OCX
Insider Trading

$OCX
SEC Filings